...Company's Phase 2 study in ColdU and SD (GlobeNewswire) - Nov 10, 2025 - "Patients were followed for up to 24 weeks after treatment completion and patients with returning or continuing symptoms were given the option to enter an open label extension (OLE) during this follow up period. Consistent with the clinical endpoint results at Week 20, placebo-treated patients entered the OLE at a faster rate compared to barzolvolimab-treated patients. The study was recently completed and data from the OLE are expected to be presented in Q1 2026."
P2 data • Trial status • Immunology • Urticaria
|